# Latigo Biotherapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/latigo-biotherapeutics

- Industry: Biotechnology
- Headquarters: Thousand Oaks, US
- Website: www.latigobio.com
- Total disclosed funding: $200M
- Latest round: Series B (Jan 28, 2025)
- Investors on record: 14

## About

Established in 2020 and based in California, US, Latigo Biotherapeutics, Inc. operates as a clinical-stage biotechnology company that develops non-opioid pain drugs. The company was founded by Sean Harper. In February 2024, Latigo Biotherapeutics, Inc. raised USD 135 million in Series A funding co-led by Westlake Village BioPartners, 5 AM Ventures, and Foresite Capital. As of 2024, the company is led by its CEO, Nima Farzan. Latigo Biotherapeutics develops non-opioid pain medicines. The firm’s lead program includes LTG-001, which is an oral, selective Na 1.8 inhibitor. The company plans to use the funds raised in February 2024 to support its portfolio development and widen its market presence.

## Funding rounds

- Series B, Jan 28, 2025, $50M — Alexandria Venture Investments, 5AM Ventures, Access Industries, Qatar Investment Authority, Sanofi Ventures, Foresite Capital, Kern Capital, Rock Springs Capital, Cormorant Asset Management, Westlake Village BioPartners, Blue Owl, Deep Track Capital, UPMC Enterprises
- Series A, Feb 14, 2024, $135M — 5AM Ventures, Foresite Capital, Westlake Village BioPartners, Corner Ventures
- Series A, Aug 21, 2020, $15M — Corner Ventures

## Investors

- Corner Ventures (https://capitalatlas.ai/funds/corner-ventures) — Series A
- 5AM Ventures (https://capitalatlas.ai/funds/5am-ventures) — Series A, Series B
- Foresite Capital (https://capitalatlas.ai/funds/foresite-capital) — Series A, Series B
- Westlake Village BioPartners (https://capitalatlas.ai/funds/westlake-village-biopartners) — Series A, Series B
- Alexandria Venture Investments (https://capitalatlas.ai/funds/alexandria-venture-investments) — Series B
- Access Industries (https://capitalatlas.ai/funds/access-industries) — Series B
- Qatar Investment Authority (https://capitalatlas.ai/funds/qatar-investment-authority) — Series B
- Sanofi Ventures (https://capitalatlas.ai/funds/sanofi-ventures) — Series B
- Kern Capital (https://capitalatlas.ai/funds/kern-capital) — Series B
- Rock Springs Capital — Series B
- Cormorant Asset Management (https://capitalatlas.ai/funds/cormorant-asset-management) — Series B
- Blue Owl (https://capitalatlas.ai/funds/blue-owl) — Series B
- Deep Track Capital (https://capitalatlas.ai/funds/deep-track-capital) — Series B
- UPMC Enterprises (https://capitalatlas.ai/funds/upmc-enterprises) — Series B